Addex Unit Neurosterix Eyes Q2 2026 Completion Of NTX-253 Phase 1 Study, Evaluating Safety And Pharmacokinetics In Schizophrenia Patients

Benzinga Newsdesk www.benzinga.com Positive 72.4%